

EFFECTIVE PHARMACOGENOMIC-DRIVEN TREATMENT OF MAJOR DEPRESSION: A CASE REPORT

Dragan Primorac^{1,2,3,4,5,6,7,8,*}, Alen Juginović¹, Igor Filipčić^{4,9,10}, Ivan Mikula¹, Ines Lazibat^{4,11},
Morana Brkljačić¹² & Damir Erceg^{1,3,4,12,13,*}

¹St. Catherine Specialty Hospital, Zagreb & Zabok, Croatia

²University of Split School of Medicine, Split, Croatia

³University of Osijek School of Medicine, Osijek, Croatia

⁴University of Osijek Faculty of Dental Medicine and Health, Osijek, Croatia

⁵University of Rijeka School of Medicine, Rijeka, Croatia

⁶Eberly College of Science, 517 Thomas St, State College, Penn State University, USA

⁷The Henry C. Lee College of Criminal Justice and Forensic Sciences, University of New Haven, West Haven, USA

⁸Medical School REGIOMED, Coburg, Germany

⁹Psychiatry Hospital „Sveti Ivan“, Zagreb, Croatia

¹⁰University of Zagreb School of Medicine, Zagreb, Croatia

¹¹Clinical Hospital Dubrava, Zagreb, Croatia

¹²Catholic University of Croatia, Zagreb, Croatia

¹³Children's Hospital Srebrnjak, Zagreb, Croatia

*These authors contributed equally to this work

received: 6.9.2020;

revised: 9.10.2020;

accepted: 16.10.2020

* * * * *

INTRODUCTION

Major depressive disorder (MDD) is a complex disorder that can affect patients' ability to sleep, work, eat, and do daily practice. It affects approximately 1 in 5 adults at least once in a lifetime (Weihs & Wert 2011). Up to a third of MDD patients have treatment-resistant depression (TRD) (Al-Harbi 2012). TRD is associated with increased suicide risk, sexual dysfunction, greater depression severity and body mass index ≥ 30 kg/m² (Saragoussi et al. 2017). Since genetic variants explain up to 42% of interindividual differences in antidepressant response, more precise and personalized way of MDD and TRD treatment such as pharmacogenomics (PGx) is necessary to improve outcomes and safety, and to reduce the economic burden of 136 billion USD annually in the United States alone associated with adverse drug reactions (Han et al. 2018, Johnson & Bootman 1995).

CASE PRESENTATION

We present a case of a 50-year-old female patient with a history of arterial hypertension, MDD, insomnia, and ineffective antidepressant (AD) therapy for 21 years. Also, her mother was treated for MDD. In 1998, the patient was diagnosed with MDD and since then has been on numerous ADs with no clinical improvement. She started in 1998 with venlafaxine 37.5 mg and in 2003 changed to paroxetine 20 mg and maprotiline 25 mg, but she was still depressed, tired, and afraid. Later, she tried using another selective serotonin

reuptake inhibitor sertraline, but it caused nausea. Computerized tomography brain scan and thyroid hormone analysis showed no pathological changes. In 2017 citalopram was introduced as new therapy, but with no improvements and some side effects. In 2018, she started using duloxetine 30 mg. Additionally, she used amitriptyline and fluvoxamine, which didn't have positive effect, and ramipril. In 2019, she was referred to St. Catherine Specialty Hospital with severe depression symptoms and thoughts of hurting others. She had reminiscent thoughts of childhood family trauma (father unintentionally cutting her arm with a knife), which she associates as the present condition's cause. Since her past medications were ineffective, we did PGx with RightMed[®] panel which determines single nucleotide polymorphisms using TaqMan real-time PCR to see if there were significant drug-drug or drug-gene interactions (DGIs). The panel analyze 111 polymorphisms in 25 genes responsible for the synthesis of drug metabolizing enzymes, drug transporters, drug receptors and other proteins important for drug function, as well as for prothrombic factors (II, V and methyltetrahydrofolate reductase (MTHFR)) (Rogulj et al. 2019). She started taking PGx-guided medications including bupropion 150 mg and trazodone 75 mg. However, because of rash, a common adverse effect, therapy was changed according to PGx to vortioxetine 10 mg (moderate DGI), quetiapine 25 mg (minimal DGI) and lorazepam (as needed) in collaboration with Psychiatry Hospital „Sveti Ivan“ Zagreb. We also introduced support 10-day deep Transcranial Magnetic Stimulation (dTMS) session. After 5-6 weeks, she felt better, slept better and had more

Table 1. Drugs the patient has used and their respective genes, genotype, phenotype and metabolic status

Gene	Genotype	Phenotype	Metabolic status	Drugs included in patient's therapy
CYP3A4	*4/*35	Normal	Normal activity	quetiapine, trazodone
CYP3A5	*1/*3	Intermediate	Decreased activity	quetiapine, trazodone
CYP2C19	*2/*2	Poor	No to very low activity	amitriptyline, sertraline, citalopram, venlafaxine
CYP2B6	*1/*1	Normal	Normal activity	bupropion
CYP2D6	*4/*35	Intermediate	Decreased activity	fluvoxamine, paroxetine, vortioxetine, venlafaxine
HRT2A	rs7997012 GG	Intron 2 genotype GG	16-18% increased risk of non-response to citalopram	citalopram
GRIK4	rs1954787 TT	Risk of reduced response	11% increase in the risk of not responding to citalopram	citalopram

energy for the first time in 21 years. Furthermore, another 6-7 weeks and five months later, the improvement in mood, cognitive functioning, and sleep continued, strengthened by improvements in Beck Depression Inventory (BDI), Hamilton Depression Rating Scale (HDRS), and Pittsburgh Sleep Quality Index (PSQI). HCL-32 Questionnaire had a score of 2/32 prior to and after new therapy, while there was a negative screen on the Mood Disorder Questionnaire (MDQ) questionnaire.

DISCUSSION

For the last 21 years, the patient has been taking 10 ADs from various groups, but with no clinical improvement. Since she came to St. Catherine Specialty Hospital in 2019, we do not know why the patient has not used lithium or undergone electroconvulsive therapy before that timepoint. Regardless, PGx-tailored therapy was the logical next step (Primorac et al. 2020). The patient's result revealed homozygous CYP2C19 genotype *2/*2, associated with poor metabolizer phenotype with no to very low enzyme activity, essential for metabolizing ADs like amitriptyline, sertraline and citalopram, which showed major DGIs (Table 1). Furthermore, venlafaxine showed moderate DGIs. Due to polymorphisms in HRT2A and GRIK4 receptors, there is significantly reduced likelihood of response to citalopram therapy (Kawaguchi & Glatt 2014, McMahon 2016). CYP2D6 genotype *4/*35, an important enzyme for metabolizing ADs like fluvoxamine and paroxetine, showed decreased activity, and together with no to very low CYP2C19 activity could explain the experienced adverse effects of amitriptyline, sertraline and citalopram due to potentially high doses administered concerning to this metabolizer.

No interactions other than between AD drugs in her therapy were noted. Following PGx results, we suggested taking bupropion and trazodone, only available ADs with minimal DGIs. Soon she had a skin rash, probably due to bupropion being a strong inhibitor of CYP2D6. This enzyme can affect trazodone metabolism, increasing the body's exposure to it. Therapy

changed to vortioxetine and quetiapine based on PGx. The introduction of an atypical antipsychotic was justified due to a hint of psychosis and the patient's thoughts of harming others. Two weeks after dTMS session, she felt better, and 5-6 weeks later she could sleep better and also further improved. Since ADs and antipsychotics usually take 5-6 weeks to fully show their clinical potential, we attribute overall improvement to PGx-guided therapy and acute improvement after 2 weeks to dTMS. Also, dTMS is most effective after longer periods, not a 10-day session (Rapinesi et al. 2015). After another 6-7 weeks and five months, she continued improving. Cognitive function and desire were regained, fatigue decreased, and she willingly returned to work. BDI, HDRS showed improvements in depression severity (BDI 25 vs. 8, HDRS 26 vs. 5). PSQI indicated overall better sleep. MDQ showed negative screen for bipolar disorder, while HCL-32 Questionnaire had a 2/32 score indicating no significant signs of bipolar disorder.

CONCLUSION

The patient has been taking 10 ADs for 21 years with no clinical effect. PGx testing showed major and moderate DGIs, as well as receptor polymorphisms which are significant in AD metabolism and could explain poor clinical outcomes. PGx-guided therapy brought us to our goals sooner, and the patient felt better, slept better, regained cognitive function and willingness to work. The results show that a personalized PGx approach in patients with TRD has great therapeutic potential.

Ethical disclosure:

The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki in 1995 (as revised in Edinburgh 2000) for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participant involved.

Financial disclosure:

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. No writing assistance was utilized in the production of this manuscript.

Acknowledgements: None.

Conflict of interest: None to declare.

Contribution of individual authors:

Dragan Primorac – Conceived and designed the study and the analysis, wrote the paper.

Alen Juginović – Collected the data and wrote the paper.

Igor Filipčić, Ivan Mikula, Ines Lazibat & Morana Brkljačić – Performed the analysis and collected the data.

Damir Erceg – Performed the analysis, collected the data and wrote the paper.

References

1. Al-Harbi KS: Treatment-resistant depression: therapeutic trends, challenges, and future directions. *Patient Prefer Adherence* 2012; 6:369
2. Han C, Wang SM, Bahk WM, Lee SJ, Patkar AA, Masand PS et al: A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder: Results from an 8-week, Randomized, Single-blinded Clinical Trial. *Clin Psychopharmacol Neurosci* 2018;16:469–480
3. Johnson JA, Bootman JL: Drug-related morbidity and mortality. A cost-of-illness model. *Arch Intern Med* 1995; 155:1949–1956
4. Kawaguchi DM, Glatt SJ: GRIK4 polymorphism and its association with antidepressant response in depressed patients: a meta-analysis. *Pharmacogenomics* 2014; 15:1451–1459
5. McMahon FJ, Buervenich S, Charney D: Variation in the Gene Encoding the Serotonin 2A Receptor Is Associated with Outcome of Antidepressant Treatment. *Am J Hum Genet* 2006; 78:804–814
6. Primorac D, Bach-Rojecky L, Vađunec D, Juginović A, Žunić K, Matišić V et al: Pharmacogenomics at the center of precision medicine: challenges and perspective in an era of Big Data. *Pharmacogenomics* 2020; 21:141-156
7. Rapinesi C, Bersani FS, Kotzalidis GD, Imperatori C, Del Casale A, DiPietro S et al.: Maintenance Deep Transcranial Magnetic Stimulation Sessions are Associated with Reduced Depressive Relapses in Patients with Unipolar or Bipolar Depression. *Front Neurol* 2015; 6:16
8. Rogulj IM, Matišić V, Arsov B, Boban L, Juginović A, Molnar V et al.: Dasatinib-induced nephrotic syndrome: a case of phenoconversion. *Croat Med J* 2019; 60:250–254
9. Saragoussi D, Touya M, Haro JM, Jönsson B, Knapp M, Botrel B et al.: Factors associated with failure to achieve remission and with relapse after remission in patients with major depressive disorder in the PERFORM study. *Neuropsychiatr Dis Treat* 2017; 13:2151–65
10. Weihs K & Wert JM: A primary care focus on the treatment of patients with major depressive disorder. *Am J Med Sci* 2011; 342:324–330

Correspondence:

Prof. Dragan Primorac, MD, PhD
St. Catherine Specialty Hospital
Trpinjska 7, 10 000 Zagreb, Croatia
E-mail: office@draganprimorac.com